Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 419

Sort by

Sort Order Select

Journal Articles

Outcomes and survival prediction in adults with sickle cell disease treated with extracorporeal membrane oxygenation

Alison Grazioli, Michael Plazak, Kate Willsey, Joseph Rabin, Raymond P. Rector, Leonid Belyayev, Allison S. Lankford, Thomas M. Scalea, Aakash Shah, Bradley S. Taylor, Mark T. Gladwin

Blood Adv (2025) 9 (19): 4881–4890.

https://doi.org/10.1182/bloodadvances.2025016368

Published: 2025

Includes: Supplemental data

Journal Articles

A standardized metric to define a successful transition from pediatric to adult care in sickle cell disease

Galia Pollock, Susanna Curtis

Blood Adv (2025) 9 (18): 4622–4623.

https://doi.org/10.1182/bloodadvances.2025017088

Published: 2025

Journal Articles

Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: a SEER-Medicare data analysis

Andrea P. Chung, Jason T. Shafrin, Sachin Vadgama, Kristen Hurley, Miguel-Angel Perales, Leonard C. Alsfeld, Sanjana Muthukrishnan, Anik R. Patel, Gunjan L. Shah, Richard T. Maziarz

Blood Adv (2025) 9 (18): 4727–4735.

https://doi.org/10.1182/bloodadvances.2024015634

Published: 2025

Includes: Supplemental data

Journal Articles

TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas

Pierre Stephan, Roberta Di Blasi, Louise Roulin, Jean Galtier, Julien Calvani, Véronique Meignin, Marie Donzel, Alexandra Traverse-Glehen, Elsa Poullot, Marie Parrens, Vivien Dupont, Alexandra Marquet, Steven Le Gouill, Roch Houot, Francois-Xavier Gros, François Lemonnier, Emmanuel Bachy, Catherine Thieblemont, Pierre Sesques

Blood Adv (2025) 9 (18): 4693–4704.

https://doi.org/10.1182/bloodadvances.2025015834

Published: 2025

Includes: Supplemental data

Journal Articles

Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels

Rahul Banerjee, Meera Mohan, Kai Rejeski, Benjamin R. Puliafito, Diana D. Cirstea, Gurbakhash Kaur, Shonali Midha, Georgia J. McCaughan, Nikhil M. Kumar, Nikita Mehra, Bhausaheb Bagal, Noopur S. Raje

Blood Adv (2025) 9 (18): 4720–4726.

https://doi.org/10.1182/bloodadvances.2025016490

Published: 2025

Journal Articles

Estimation of benefit to bispecific antibodies in US patients with lymphoma and multiple myeloma

Fausto Alfredo Rios-Olais, Talal Hilal

Blood Adv (2025) 9 (18): 4673–4675.

https://doi.org/10.1182/bloodadvances.2025016176

Published: 2025

Includes: Supplemental data

Journal Articles

National Alliance of Sickle Cell Centers consensus standards for transition to adult care in sickle cell disease

Stephanie Howe Guarino, Akshat Jain, Mohan Madisetti, Kenneth Rivlin, Payal C. Desai, Julie Kanter, Sophie Lanzkron, Deepa Manwani

Blood Adv (2025) 9 (18): 4585–4591.

https://doi.org/10.1182/bloodadvances.2025015909

Published: 2025

Includes: Supplemental data

Journal Articles

Biological Parenthood Rates Among Men with Sickle Cell Disease

Anyssa N Young, Sarah R Hayford, Sapuni S Chandrasena, Sara Conroy, Tanvi Karkare, Barbara L. Kroner, Allison A King, Robert M Cronin, Luca Badolato, Leena Nahata, Susan E Creary

Blood Adv bloodadvances.2025017458.

https://doi.org/10.1182/bloodadvances.2025017458

Published: 2025

Journal Articles

An AI Model Classifies Risks of Early Relapse Post-CAR T Cell Therapy in a Multi-Center Real-World Population with DLBCL

Michelle Wang, Krishna V Komanduri, Debajyoti Datta, Ayan Patel, Barbee Whitaker, Artur Belov, Benjamin Rubin, Rohit Vashist, Rosa Rodriguez-Monguio, Pelin Cinar, Steven A. Anderson, Atul J. Butte

Blood Adv bloodadvances.2025016375.

https://doi.org/10.1182/bloodadvances.2025016375

Published: 2025

Includes: Supplemental data

Journal Articles

Moving beyond the eyeball test for fitness assessment in AML

Samuel J. Yates, Heidi D. Klepin

Blood Adv (2025) 9 (17): 4488–4490.

https://doi.org/10.1182/bloodadvances.2025016235

Published: 2025

Journal Articles

A mixed methods study to understand the role of knowledge in transition among youth with sickle cell disease

Ashima Singh, Mahua Dasgupta, M. Muska Nataliansyah, Nicole Steiner, Jeffrey Karst, Meghan Miller, Joshua J. Field, Melissa Azul, Liliana E. Pezzin, Amanda M. Brandow

Blood Adv (2025) 9 (17): 4477–4485.

https://doi.org/10.1182/bloodadvances.2025015984

Published: 2025

Includes: Supplemental data

Journal Articles

Association of sleep study outcomes and health care utilization in children with sickle cell disease: a multicenter study

Ammar Saadoon Alishlash, Anis Rabbani Nourani, Dima Ezmigna, Tarig Ali-Dinar

Blood Adv (2025) 9 (17): 4491–4499.

https://doi.org/10.1182/bloodadvances.2025016312

Published: 2025

Journal Articles

Racial disparities in the management of deep vein thrombosis from a nationwide hospitalization study

Jayalekshmi Jayakumar, Manasa Ginjupalli, Nikhil Vojjala, Davin Turku, Fiqe Khan, Srijani Thannir, Aju Kalaivani Babu, Srinishant Rajarajan, Tijin Ann Mathew, Arya Mariam Roy

Blood Adv (2025) 9 (17): 4364–4367.

https://doi.org/10.1182/bloodadvances.2025016171

Published: 2025

Journal Articles

SGLT2i-associated erythrocytosis: closing the evidence gap

Benjamin Chin-Yee, Cyrus C. Hsia

Blood Adv (2025) 9 (16): 4321–4322.

https://doi.org/10.1182/bloodadvances.2025016967

Published: 2025

Journal Articles

Long-term outcomes of patients with refractory cytopenia of childhood under observation only

Beatrice Drexler, Stephan Schwarz-Furlan, Irith Baumann, Martina Rudelius, Peter Nöllke, Dirk Lebrecht, Senthilkumar Ramamoorthy, Natalia Rotari, Axel Karow, Shinsuke Hirabayashi, Fabian Beier, Yvonne Lisa Behrens, Gudrun Göhring, Reinhard Kalb, Marcin W. Wlodarski, Brigitte Strahm, Miriam Erlacher, Charlotte M. Niemeyer, Ayami Yoshimi

Blood Adv (2025) 9 (16): 4279–4285.

https://doi.org/10.1182/bloodadvances.2025016136

Published: 2025

Includes: Supplemental data

Journal Articles

Role of race and ethnicity in survival among children/young adults with relapsed ALL: a Children's Oncology Group report

Blood Adv bloodadvances.2025016670.

https://doi.org/10.1182/bloodadvances.2025016670

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement

Blood Adv (2025) 9 (16): 4081–4089.

https://doi.org/10.1182/bloodadvances.2024015779

Published: 2025

Journal Articles

Biomarker signatures for sickle cell pain

Kalpna Gupta, Vidhya Kumaresan

Blood Adv (2025) 9 (15): 3821–3823.

https://doi.org/10.1182/bloodadvances.2025016707

Published: 2025

Journal Articles

Accelerating Novel Therapies for Sickle Cell Disease with RWE: ASH RC Data Hub as a Strategically Coordinated Registry Network

William A Wood, Osman N Yogurtcu, Emily Semmel, Kathleen Torres (formerly Hewitt), Donna S. Neuberg, Lea B Witkowsky, Ken Taymor, Santiago J Molina, Jane S Hankins, Alexis A. Thompson, Gregory Pappas

Blood Adv bloodadvances.2024015532.

https://doi.org/10.1182/bloodadvances.2024015532

Published: 2025

Includes: Supplemental data

Journal Articles

Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis

Blood Adv bloodadvances.2025016315.

https://doi.org/10.1182/bloodadvances.2025016315

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Outcomes and survival prediction in adults with sickle cell disease treated with extracorporeal membrane oxygenation

A standardized metric to define a successful transition from pediatric to adult care in sickle cell disease

Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: a SEER-Medicare data analysis

TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas

Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels

Estimation of benefit to bispecific antibodies in US patients with lymphoma and multiple myeloma

National Alliance of Sickle Cell Centers consensus standards for transition to adult care in sickle cell disease

Biological Parenthood Rates Among Men with Sickle Cell Disease

An AI Model Classifies Risks of Early Relapse Post-CAR T Cell Therapy in a Multi-Center Real-World Population with DLBCL

Moving beyond the eyeball test for fitness assessment in AML

A mixed methods study to understand the role of knowledge in transition among youth with sickle cell disease

Association of sleep study outcomes and health care utilization in children with sickle cell disease: a multicenter study

Racial disparities in the management of deep vein thrombosis from a nationwide hospitalization study

SGLT2i-associated erythrocytosis: closing the evidence gap

Long-term outcomes of patients with refractory cytopenia of childhood under observation only

Role of race and ethnicity in survival among children/young adults with relapsed ALL: a Children's Oncology Group report

Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement

Biomarker signatures for sickle cell pain

Accelerating Novel Therapies for Sickle Cell Disease with RWE: ASH RC Data Hub as a Strategically Coordinated Registry Network

Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only